Jay W Heinecke

US Patent:

6939716, Sep 6, 2005

Filed:

Aug 22, 2002

Appl. No.:

10/225700

Inventors:

Jay W. Heinecke - Seattle WA, US

Assignee:

Washington University - St. Louis MO

International Classification:

G01N033/00

US Classification:

436 89, 436173, 436811, 435 71, 435 792, 435 4052, 435 696

Abstract:

The disclosure describes a method for detecting conditions indicative of sepsis. In one embodiment of the invention, an increase in the level of 3-chlorotyrosine or 3-bromotyrosine from the normal level in a sample of body fluid or tissue is indicative of early sepsis or infection. In another embodiment of the invention, the level of 3-chlorotyrosine or 3-bromotyrosine is measured or monitored to determine the response to therapeutic treatment of the infective condition in which a reduction in the level that existed prior to the treatment is an early sign or indication that the treatment is working in vivo. In a preferred embodiment, the method of the invention is illustrated in a clinically relevant mouse model of sepsis.

US Patent:

7749729, Jul 6, 2010

Filed:

Jul 19, 2005

Appl. No.:

11/572308

Inventors:

Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

G01N 33/53

US Classification:

435 41

Abstract:

The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.

US Patent:

7972802, Jul 5, 2011

Filed:

Oct 31, 2005

Appl. No.:

11/263553

Inventors:

Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

G01N 1/00
G01N 33/53

US Classification:

435 721, 435 71, 436501, 436518

Abstract:

The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.

US Patent:

8241861, Aug 14, 2012

Filed:

Jul 8, 2009

Appl. No.:

12/499711

Inventors:

Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US

Assignee:

Insilicos, LLC - Seattle WA
University of Washington - Seattle WA

International Classification:

G01N 31/00
G01N 33/53

US Classification:

435 721, 435 71, 436501, 436518, 424 91, 424520, 422 50, 530300, 530350

Abstract:

The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an HDL subfraction, or in a complex containing apoA-I or apoA-II isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.

US Patent:

8420337, Apr 16, 2013

Filed:

May 10, 2011

Appl. No.:

13/104757

Inventors:

Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

G01N 31/00
G01N 33/53

US Classification:

435 721, 435 71, 436501, 436518

Abstract:

The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop, or is suffering from, cardiovascular disease. The methods comprise detecting an amount of at least one biomarker in a biological sample, or HDL subfraction thereof, from the subject, and comparing the detected amount of the biomarker to a predetermined value, where a difference between the detected amount and the predetermined value is indicative of the presence or risk of cardiovascular disease in the subject. In some embodiments, the biomarker comprises at least one of ApoC-IV, Paraoxonase 1, C3, C4, ApoA-IV, ApoE, ApoL1, C4B1, Histone H2A, ApoC-II, ApoM, Vitronectin, Haptoglobin-related protein, and Clusterin, or combinations thereof.

US Patent:

8460889, Jun 11, 2013

Filed:

Jul 6, 2012

Appl. No.:

13/543745

Inventors:

Jay W. Heinecke - Seattle WA, US
Tomas Vaisar - Bellevue WA, US
Bryan Prazen - Seattle WA, US
Erik Nilsson - Seattle WA, US

Assignee:

University of Washington - Seattle WA
Insilicos, LLC - Seattle WA

International Classification:

G01N 33/53
G01N 31/00

US Classification:

435 721, 435 71, 436501, 436518, 422 50, 422430, 530300, 530350

Abstract:

The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an HDL subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.

US Patent:

8541236, Sep 24, 2013

Filed:

Dec 6, 2007

Appl. No.:

11/952044

Inventors:

Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US
Michael N. Oda - Fairfield CA, US

Assignee:

University of Washington - Seattle WA
The Children's Hospital & Research Center At Oakland - Oakland CA

International Classification:

C12N 15/00
C12P 21/06
A61K 38/00
A61K 38/16
C07K 14/775

US Classification:

435440, 435 691, 514 74, 514 212, 530350

Abstract:

In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux.

US Patent:

20100297680, Nov 25, 2010

Filed:

May 21, 2010

Appl. No.:

12/785332

Inventors:

Jay W. Heinecke - Seattle WA, US
John F. Oram - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

G01N 33/53
C12Q 1/02
G01N 33/92
G01N 33/543
G01N 33/68
G01N 33/50
G01N 27/447

US Classification:

435 792, 435 29, 435 71, 436 71, 436518, 436 86, 436129, 204451

Abstract:

The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.